相关实验视频
Updated: Jul 16, 2025
09:09
In Silico Clinical Trials for Cardiovascular Disease
Published on: May 27, 2022
1.8K
SGLT2 抑制剂:基于证据的关于心血管影响的更新
Imma Forzano1, Scott Wilson2,3, Angela Lombardi3
1International Translational Research and Medical Education (ITME) Consortium, Academic Research Unit, Department of Advanced Biomedical Sciences, "Federico II" University, Naples, Italy.
Expert opinion on investigational drugs
|September 23, 2023
概括
糖共传输体2 (SGLT2) 抑制剂,或gliflozins,对于糖尿病治疗至关重要,并显示出显著的心脏保护益处,即使在非糖尿病患者. 目前正在进行的研究正在探索它们对心血管的应用以及潜在的非目标效应.
科学领域:
- 心脏病学 心脏病学
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 葡萄糖共运输体2 (SGLT2) 抑制剂,也称为gliflozins,已成为糖尿病的治疗方法.
- 最近的临床试验显示,gliflozins具有显著的心脏保护作用,独立于其降糖作用.
- 这些发现扩大了SGLT2抑制剂的治疗领域,超出了糖尿病管理范围.
研究的目的:
- 总结一下SGLT2抑制剂在心血管应用方面的最新进展.
- 批判性地评估临床研究的合理性和结果关于gliflozins和心血管疾病.
- 提供正在进行的研究SGLT2抑制剂在心血管医学中的试验概述.
主要方法:
- 关于SGLT2抑制剂的最近随机临床试验和临床前发现的综述.
- 批判性地检查研究的理由,方法和结果.
- 综合当前的知识和确定未来的研究方向.
主要成果:
- SGLT2 抑制剂具有显著的心脏保护作用,对糖尿病患者和非糖尿病患者都有好处.
- 临床试验结果已经扩大了gliflozins的治疗指示.
- 新出现的临床前数据表明潜在的非目标效应需要进一步调查.
结论:
- SGLT2 抑制剂代表了心血管医学的重大治疗进步.
- 需要进一步的研究,以充分阐明gliflozins的心血管益处和潜在风险.
- 目前正在进行的试验对于解决关于心血管疾病中gliflozins的剩余问题至关重要.
相关概念视频
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
2.9K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
2.9K
01:27Glucose Transporters
22.9K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
22.9K
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
552
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
552
01:30Heart Failure V: Medical Management
12
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
12
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
223
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
223
01:23Dipeptidyl Peptidase 4 Inhibitors
204
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
204